Since January 2026, Solventum has been in a holding pattern, posting a small loss of 2.2% while floating around $77.29. The stock also fell short of the S&P 500’s 7.9% gain during that period.
Is now the time to buy Solventum, or should you be careful about including it in your portfolio? See what our analysts have to say in our full research report, it’s free.
Why Do We Think Solventum Will Underperform?
We’re sitting this one out for now. Here are three reasons why there are better opportunities than SOLV, plus one stock we’d rather own.
1. Slow Organic Growth Suggests Waning Demand In Core Business
We can better understand Surgical Equipment & Consumables - Diversified companies by analyzing their organic revenue. This metric gives visibility into Solventum’s core business because it excludes one-time events such as mergers, acquisitions, and divestitures along with foreign currency fluctuations - non-fundamental factors that can manipulate the income statement.
Over the last two years, Solventum’s organic revenue averaged 2.4% year-on-year growth. This performance slightly lagged the sector and suggests it may need to improve its products, pricing, or go-to-market strategy, which can add an extra layer of complexity to its operations. 
2. Projected Revenue Growth Shows Limited Upside
Forecasted revenues by Wall Street analysts signal a company’s potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite.
Over the next 12 months, sell-side analysts expect Solventum’s revenue to stall, close to its 1.3% annualized growth for the past three years. This projection doesn’t excite us and suggests its newer products and services will not accelerate its top-line performance yet.
3. Free Cash Flow Margin Dropping
If you’ve followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can’t use accounting profits to pay the bills.
As you can see below, Solventum’s margin dropped by 30.8 percentage points over the last five years. If its declines continue, it could signal increasing investment needs and capital intensity. Solventum’s free cash flow margin for the trailing 12 months was negative 2.5%.
Final Judgment
We cheer for all companies helping people live better, but in the case of Solventum, we’ll be cheering from the sidelines. With its shares lagging the market recently, the stock trades at 11.5× forward P/E (or $77.29 per share). While this valuation is fair, the upside isn’t great compared to the potential downside. There are better investments elsewhere. We’d recommend looking at a top digital advertising platform riding the creator economy.
Stocks We Like More Than Solventum
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
